Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.83 Consensus Price Target from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $14.8333.

Several equities research analysts recently weighed in on KPTI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a research note on Wednesday, December 17th. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating for the company. Royal Bank Of Canada dropped their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 4th. Finally, Piper Sandler restated an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th.

Karyopharm Therapeutics Stock Down 4.0%

KPTI stock opened at $8.58 on Thursday. The stock’s 50 day moving average is $6.98 and its 200-day moving average is $6.25. The firm has a market capitalization of $157.10 million, a PE ratio of -0.52 and a beta of 0.21. Karyopharm Therapeutics has a twelve month low of $3.51 and a twelve month high of $10.38.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.03. The business had revenue of $34.08 million for the quarter, compared to analysts’ expectations of $33.16 million. On average, equities research analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Baird Financial Group Inc. bought a new position in shares of Karyopharm Therapeutics in the second quarter worth about $45,000. XTX Topco Ltd bought a new position in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. ADAR1 Capital Management LLC bought a new position in Karyopharm Therapeutics in the 3rd quarter worth approximately $164,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the 2nd quarter valued at approximately $163,000. Finally, State Street Corp raised its position in shares of Karyopharm Therapeutics by 27.2% during the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after buying an additional 12,600 shares during the last quarter. Institutional investors own 66.44% of the company’s stock.

Trending Headlines about Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Q4 results slightly beat estimates — GAAP loss per share was ($2.23) vs. consensus ($2.26), and revenue of $34.08M topped estimates ($33.16M). The beat reduces downside from the report itself. Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Near‑term clinical catalysts: top‑line Phase 3 SENTRY data in myelofibrosis expected in March 2026 and Phase 3 XPORT‑EC‑042 endometrial cancer readout mid‑2026 — binary outcomes that could drive material upside if positive. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
• Neutral Sentiment: Earnings-call materials and full transcripts are available for review — useful for gauging management tone on commercialization and trial timelines but not immediate price movers by themselves. Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported large increases in short interest appear to be data errors (entries show 0 shares / NaN). Short‑interest figures are unreliable at present and should be rechecked before drawing conclusions.
• Negative Sentiment: Full‑year 2026 revenue guidance of $130M–$150M (U.S. XPOVIO net product revenue guidance $115M–$130M) is cautious versus the published consensus (~$145.3M), leaving the midpoint below consensus and prompting investor concern about growth trajectory. Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.